Preclinical Research

The 2026 Mateescu Pharmaceutics review (doi:10.3390/pharmaceutics18050625) identifies a fundamental asymmetry in BPC-157's route-of-administration evidence: oral delivery has the strongest mechanistic rationale for gastrointestinal indications because luminal — not systemic — exposure is the therapeutic target, while parenteral routes face a sub-16-minute intravenous half-life and species-variable intramuscular bioavailability (14–51%) that undermine systemic exposure modelling.

The July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, KPV, and TB-500 for the 503A Bulks List, and 7-5 for MOTS-c — overriding staff's negative briefing documents. The vote is non-binding; formal rulemaking must follow. Retatrutide was not evaluated under this framework: it is advancing toward a 2027 BLA filing on Phase 3 RCT data.

As of mid-2026, no completed randomized controlled trial has evaluated BPC-157 in any acute human muscle injury indication. The musculoskeletal efficacy record is entirely preclinical. One Phase 2 RCT — NCT07437547, targeting acute grade II hamstring strain — is recruiting, with co-primary endpoints of MRI-assessed injury volume at Day 14 and time to return to unrestricted sport.

Cone snail venom peptides — principally μ-, ω-, and α-conotoxin classes — reduce inflammation-induced pain in vivo through at least three mechanistically distinct pathways: voltage-gated sodium channel (NaV1.7/NaV1.8) blockade that silences peripheral nociceptor firing, N-type calcium channel (CaV2.2) inhibition that curtails spinal neurotransmitter release, and suppression of the NF-κB/COX-2 axis that drives prostaglandin-mediated peripheral sensitisation.

VRB-103 is a once-weekly oral amylin analog entering Phase 1 development by Verdiva Bio, with first-patient dosing confirmed in late July 2026. Whether it reproduces injectable-style weight-loss efficacy depends on three unresolved variables: oral bioavailability at therapeutically relevant concentrations, retention of AMY receptor selectivity after structural modification, and a tolerability profile that improves on pramlintide's nausea burden.

As of mid-2026, TB-500's wound-healing evidence base is mechanistically coherent and preclinically robust, but no completed human randomised controlled trial has evaluated the compound in any wound-healing indication. The July 2026 FDA PCAC review identified this absence as the definitive barrier to 503A compounding eligibility. The human trial gap is not narrowing — it remains structurally unbridged.

Both GIPR agonism and GIPR antagonism reduce body weight in preclinical models, creating a pharmacological paradox unresolved as of 2026. GIPR agonism in hypothalamic neurons suppresses food intake, while GIPR antagonism in peripheral adipose tissue blocks lipid storage. Tirzepatide's clinical success as a GIPR agonist does not invalidate the antagonist data — it reflects a different mechanistic axis.

Phase II data for sonefpeglutide — a long-acting GLP-1/GIP/glucagon triple receptor co-agonist — demonstrate clinically meaningful reductions in hepatic steatosis, NAS score components, and fibrosis stage in biopsy-confirmed MASH. MRI-PDFF liver-fat reduction exceeded 50% relative from baseline at the highest doses, and a substantial proportion of participants achieved MASH resolution without fibrosis worsening, meeting the FDA's accepted surrogate histological endpoint.

The FDA's 2026 PCAC actions against BPC-157, TB-500, MOTS-C, GHK-Cu, and Semax reflect regulatory process — not clinical validation or invalidation. All five compounds were evaluated under the 503A Bulks List framework, which requires human safety and efficacy data that none of them possesses. The regulatory outcome maps to an evidence gap, not a clinical verdict.

BPC-157 has no confirmed membrane receptor as of 2026. A 2026 review in Pharmaceutics by Mateescu and colleagues identifies this receptor-orphan status as the root obstacle to rational analogue design. Without a defined pharmacophore, structure–activity relationship studies cannot guide modifications improving half-life, permeability, or potency. Downstream signalling through Egr-1, FAK–paxillin, and VEGFR2 is characterised, but the upstream receptor remains unknown.

At its July 23–24, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended against adding BPC-157 to the 503A Bulks List, citing three biopharmaceutical deficiencies: injectable immunogenicity risk, uncharacterised peptide impurity profiles, and an absence of clinical safety data — gaps catalogued independently in the 2026 Pharmaceutics review by Mateescu et al. (doi:10.3390/pharmaceutics18050625).

A 2026 review in Expert Opinion on Drug Delivery identifies three sequential gastrointestinal barriers as the principal reasons oral semaglutide bioavailability remains approximately 0.4 to 1 percent despite SNAC co-formulation. Acid-mediated unfolding, pepsin proteolysis, and low epithelial permeability each require distinct mechanistic solutions. The review proposes ionic-liquid enteric systems, lipid nanocarriers, and extracellular vesicle platforms as targeted responses.